NASDAQ:ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.'s revenue grew 23258.2% in fiscal 2025 to $829.4M while operating margin rose to 11.9%. Free cash flow was $156.9M, 18.9% of revenue, and the diluted share count rose 11.7%.Summary generated from Arrowhead Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Nov 25, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$829.4M
Revenue growth+23258.2%
Revenue, 5-yr CAGR+56.6%
Gross marginn/a
Operating margin11.9%
Net margin−0.2%
ROICn/a
Return on equity−0.5%
Debt / equityn/a
Free cash flow$156.9M
FCF margin18.9%
Share count change+11.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 138 | 243 | 241 | 4 | 829 |
| Operating income | −149 | −179 | −205 | −601 | 98 |
| Net income | −141 | −176 | −205 | −599 | −2 |
| Free cash flow | 148 | −189 | −331 | −604 | 157 |
Recent filings
- 4Insider transaction report
Aug 20, 2026 - 4Insider transaction report
Aug 20, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KDirector or officer change
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - 8-KResults of a shareholder vote
Mar 20, 2026